Scientists have developed the first broad-based test for activation of protein kinases “en masse”, enabling measurement of the mechanism behind drug-resistant cancer and rational prediction of successful combination therapies.
Scientists have developed the first broad-based test for activation of protein kinases “en masse”, enabling measurement of the mechanism behind drug-resistant cancer and rational prediction of successful combination therapies.